中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.015 seconds)

    BIOMARKERS RELATED TO ORGAN FUNCTION
    1.
    发明申请
    BIOMARKERS RELATED TO ORGAN FUNCTION 审中-公开
    与机关功能相关的生物标志

    公开(公告)号：WO2015042602A1

    公开(公告)日：2015-03-26

    申请号：PCT/US2014/057049

    申请日：2014-09-23

    Applicant: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ,  CHAVES FONTES, Paulo, A. ,  KELLUM, John, A.

    Inventor： CHAVES FONTES, Paulo, A. ,  KELLUM, John, A.

    IPC: C12Q1/68

    CPC classification number: G01N33/6863 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N33/6866 ,  G01N33/6869 ,  G01N2333/525 ,  G01N2333/5406 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/5428 ,  G01N2333/5434 ,  G01N2333/545 ,  G01N2333/56 ,  G01N2333/57 ,  G01N2570/00 ,  G01N2800/085 ,  G01N2800/50 ,  G01N2800/60

    Abstract: Disclosed herein are methods of identifying biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) that can be used to predict organ or tissue function or dysfunction. In some embodiments, the methods include ex vivo perfusion of the organ or tissue, collection of samples from the organ or tissue (for example, perfusate, fluids produced by the organ (such as bile or urine), or tissue biopsies) and measuring the level of one or more biomarkers in the sample. It is also disclosed herein that an analysis of biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) present in a biological sample from an organ, tissue, or subject can be used to identify whether the organ, tissue, or subject is at risk for (or has) organ dysfunction or organ failure.

    Abstract translation: 本文公开了可用于预测器官或组织功能或功能障碍的生物标志物（例如基因（例如RNA或mRNA），蛋白质和/或小分子）的方法。 在一些实施方案中，所述方法包括器官或组织的离体灌注，来自器官或组织（例如，灌注液，由器官（如胆汁或尿液）产生的流体）或组织活组织检查）的样品的收集，并测量 样品中一种或多种生物标志物的水平。 本文还公开了可以使用存在于来自器官，组织或受试者的生物样品中的生物标志物（例如RNA或mRNA），蛋白质和/或小分子的分析来鉴定是否 器官，组织或受试者处于（或具有）器官功能障碍或器官衰竭的风险中。

    URINE BIOMARKERS FOR PREDICTION OF RECOVERY AFTER ACUTE KIDNEY INJURY : PROTEOMICS
    3.
    发明申请
    URINE BIOMARKERS FOR PREDICTION OF RECOVERY AFTER ACUTE KIDNEY INJURY : PROTEOMICS 审中-公开
    尿液生物标志物在急性KIDNEY伤害后预防恢复：PROTEOMICS

    公开(公告)号：WO2012102963A1

    公开(公告)日：2012-08-02

    申请号：PCT/US2012/022028

    申请日：2012-01-20

    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ,  SINGBARTL, Kai ,  KELLUM, John, A.

    Inventor： SINGBARTL, Kai ,  KELLUM, John, A.

    IPC: G01N33/50 ,  G01N33/53 ,  A61M1/14

    CPC classification number: G01N33/6893 ,  G01N2800/347 ,  G01N2800/52 ,  G01N2800/60

    Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal recovery and/or renal non-recovery.

    Abstract translation: 本发明涉及肾脏疾病的预防和治疗领域。 肾脏疾病的治疗可以根据肾脏恢复的需要或预期来定制。 例如，可以通过监测与慢性肾脏疾病发展相关的尿生物标志物来确定肾脏恢复。 例如，测量尿蛋白的大约十四天的标准化时间过程可用于确定患有急性肾损伤的患者的恢复与非恢复的风险。 或者，本发明描述了确定肾脏恢复和/或肾脏不恢复的可能性的特征蛋白表达谱。

    BIOMARKERS OF RENAL INJURY
    4.
    发明申请
    BIOMARKERS OF RENAL INJURY 审中-公开

    公开(公告)号：WO2012040073A3

    公开(公告)日：2012-03-29

    申请号：PCT/US2011/052082

    申请日：2011-09-19

    Applicant: UNIVERSITY OF PITTSBURGH -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ,  SINGBARTL, Kai ,  KELLUM, John, A.

    Inventor： SINGBARTL, Kai ,  KELLUM, John, A.

    IPC: G01N33/50 ,  G01N33/68

    Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor β1 can be used to establish the risk of recovery versus non-recovery in patient' s having suffered an acute kidney injury.

    BIOMARKERS OF RENAL INJURY
    5.
    发明申请
    BIOMARKERS OF RENAL INJURY 审中-公开
    肾损伤的生物标志物

    公开(公告)号：WO2012040073A2

    公开(公告)日：2012-03-29

    申请号：PCT/US2011052082

    申请日：2011-09-19

    Applicant: UNIV PITTSBURGH ,  SINGBARTL KAI ,  KELLUM JOHN A

    Inventor： SINGBARTL KAI ,  KELLUM JOHN A

    IPC: G01N33/50 ,  G01N33/68

    CPC classification number: G01N33/6893 ,  G01N2333/495 ,  G01N2333/70578 ,  G01N2400/40 ,  G01N2800/347 ,  G01N2800/50

    Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ß1 can be used to establish the risk of recovery versus non-recovery in patient' s having suffered an acute kidney injury.

    Abstract translation: 本发明涉及肾病防治领域。 根据对长期透析的需求或期望，可以对肾脏疾病的治疗进行调整。 例如，长期透析治疗的预测可以通过监测与慢性肾病发展有关的尿液生物标记来确定。 例如，测量透明质酸，死亡受体5和/或转化生长因子β1的大约十四天的标准化时间过程可用于确定患有急性肾损伤的患者恢复与不恢复的风险。

    ADMINISTRATION OF AN ADSORBENT POLYMER FOR TREATMENT OF SYSTEMIC INFLAMMATION
    6.
    发明申请
    ADMINISTRATION OF AN ADSORBENT POLYMER FOR TREATMENT OF SYSTEMIC INFLAMMATION 审中-公开
    用于治疗系统性炎症的吸收聚合物的管理

    公开(公告)号：WO2010040086A1

    公开(公告)日：2010-04-08

    申请号：PCT/US2009/059426

    申请日：2009-10-02

    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ,  KELLUM, John A. ,  FINK, Mitchell P.

    Inventor： KELLUM, John A. ,  FINK, Mitchell P.

    IPC: B01D11/04

    CPC classification number: A61K9/5026 ,  A61K9/0031 ,  A61K9/0065 ,  A61K9/2081 ,  A61K31/745 ,  A61K31/75 ,  A61K31/79 ,  Y02A50/411 ,  A61K2300/00

    Abstract: The invention provides a method of ameliorating systemic inflammation in a patient involving administering to the patient a therapeutically effective dose of composition including polystyrene divinyl benzene copolymer and a polyvinyl pyrrolidone polymer. More particularly, the method relates to using these polymers as an enteral sorbent preparation to remove inflammatory mediators, such as cytokines, from the intestinal lumen. The polymers can be in the form of a preparation of polystyrene divinyl benzene copolymer beads with a biocompatible polyvinyl pyrrolidone polymer coating.

    Abstract translation: 本发明提供了一种改善患者全身炎症的方法，其涉及向患者施用治疗有效剂量的组合物，包括聚苯乙烯二乙烯基苯共聚物和聚乙烯吡咯烷酮聚合物。 更具体地说，该方法涉及使用这些聚合物作为肠内吸收剂制剂从肠腔中除去炎症介质，如细胞因子。 聚合物可以是具有生物相容性聚乙烯吡咯烷酮聚合物涂层的聚苯乙烯二乙烯基苯共聚物珠的制备形式。

Patent Agency Ranking